15.11.2021 10:25:29
|
DGAP-News: Sangui BioTech International Inc.: - Sales of USD 18,560 in first quarter - Reduction of the operating loss
DGAP-News: Sangui Biotech International Inc.
/ Key word(s): Quarter Results
Sangui BioTech: - Sales of USD 18,560 in first quarter
Operating expenses decreased USD 2,187 or 3% to USD 62,103 during the first quarter. As a result of the above factors, the three month operating loss decreased USD 867 to USD 43,543. Due to the higher exchange rate of the US Dollar to the EURO compared to the previous year's reporting date and the resulting increased exchange rate gains from the valuation of loans denominated in EURO, the loss of the first quarter increased by USD 48,072 to USD 27,917. Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc. For more information please contact: Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
15.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
1249024 15.11.2021
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sangui Biotech International Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |